Researcher Matti Sallberg, a professor at Karolinska Institutet, Sweden, said: “The idea is that it would provide broader protection similar to that achieved after an actual infection and would be demonstrated. slightly more future-proof than vaccines currently in use.
In this newly published study, researchers show that the vaccine protects mice against severe infections from the beta variant of SARS-CoV-2, which can evade the immune response. and activate immune cells (T cells) that recognize the coronavirus found in bats.
New COVID-19 vaccine
Different vaccines have a very important role in preventing the pandemic caused by the SARS-CoV-2 coronavirus. One challenge is the virus’s ability to mutate, i.e. its ability to change to avoid a defensive human response.
Most current vaccines are based on using parts of so-called mutant coronavirus proteins to trigger the body’s immune response to the virus. It is a good vaccine protein to use, but unfortunately it is a mutant protein where mutations frequently occur that can affect the effectiveness of the vaccine.
As a result, researchers are developing a vaccine that contains more parts of the virus, including those that don’t mutate at a similar rate to the mutant protein.
In this case, it involved the DNA for parts of the mutant protein from three different coronavirus variants and the DNA for two other viral proteins, called M and N, where mutations were less common.